Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the quick ratio (acid-test) high or low?
The quick ratio (acid-test) of 1.20 is 11% above its 5-year average of 1.09, around the middle of its 5-year range (0.89–1.41).
As of the fiscal period ended Tuesday, June 30, 2026. 4.10% above its 12-month average of 1.16.
Reported quarterly quick ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 1.20.
QUICK RATIO (ACID-TEST)
1.20
QUICK RATIO (ACID-TEST) AVG TTM
1.16
QUICK RATIO (ACID-TEST) AVG 3Y
1.13
QUICK RATIO (ACID-TEST) AVG 5Y
1.09
QUICK RATIO (ACID-TEST) AVG 10Y
N/A
QUICK RATIO (ACID-TEST) AVG 15Y
N/A
QUICK RATIO (ACID-TEST) AVG 20Y
N/A
CURRENT VS TTM AVG
+4.10%
CURRENT VS 3Y AVG
+6.17%
CURRENT VS 5Y AVG
+10.96%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.35
median of 871 covered companies
CURRENT VS SECTOR MEDIAN
-64.04%
vs the sector median at left
The Pennant Group, Inc.
Market Cap
$1.39B
Quick Ratio (Acid-Test)
1.20
TTM Avg
1.16
3Y Avg
1.13
5Y Avg
1.09
Market Cap
$1.40B
Quick Ratio (Acid-Test)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.40B
Quick Ratio (Acid-Test)
11.11
TTM Avg
12.01
3Y Avg
12.01
5Y Avg
12.01
Market Cap
$1.40B
Quick Ratio (Acid-Test)
17.76
TTM Avg
8.82
3Y Avg
5.82
5Y Avg
10.42
Market Cap
$1.37B
Quick Ratio (Acid-Test)
5.07
TTM Avg
3.94
3Y Avg
5.82
5Y Avg
6.31
Market Cap
$1.42B
Quick Ratio (Acid-Test)
5.61
TTM Avg
9.29
3Y Avg
11.65
5Y Avg
16.84
Market Cap
$1.43B
Quick Ratio (Acid-Test)
1.56
TTM Avg
2.29
3Y Avg
2.59
5Y Avg
3.62
Market Cap
$1.34B
Quick Ratio (Acid-Test)
1.94
TTM Avg
2.22
3Y Avg
2.95
5Y Avg
3.44
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| The Pennant Group, Inc. (PNTG) | $1.39B | 1.20 | 1.16 | 1.13 | 1.09 |
| Braveheart Bio, Inc. (BRVE)vs › | $1.40B | N/A | N/A | N/A | N/A |
| Kailera Therapeutics, Inc. (KLRA)vs › | $1.40B | 11.11 | 12.01 | 12.01 | 12.01 |
| Taysha Gene Therapies, Inc. (TSHA)vs › | $1.40B | 17.76 | 8.82 | 5.82 | 10.42 |
| Inhibrx Biosciences Inc. (INBX)vs › | $1.37B | 5.07 | 3.94 | 5.82 | 6.31 |
| AnaptysBio, Inc. (ANAB)vs › | $1.42B | 5.61 | 9.29 | 11.65 | 16.84 |
| Ultragenyx Pharmaceutical Inc. (RARE)vs › | $1.43B | 1.56 | 2.29 | 2.59 | 3.62 |
| Omeros Corporation (OMER)vs › | $1.34B | 1.94 | 2.22 | 2.95 | 3.44 |
| Certara, Inc. (CERT)vs › | $1.44B | 2.55 | 2.09 | 2.53 | 2.95 |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.45B | 2.94 | 3.04 | 2.84 | 2.90 |
Quick Ratio
1.20
Excludes inventory
Current Ratio
1.20
Includes inventory
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2026-06-30 | 1.20 |
| 2026-03-31 | 1.19 |
| 2025-12-31 | 1.14 |
| 2025-09-30 | 1.04 |
| 2025-06-30 | 1.21 |
| 2025-03-31 | 1.41 |
| 2024-12-31 | 1.21 |
| 2024-09-30 | 1.12 |
| 2024-06-30 | 1.12 |
| 2024-03-31 | 1.16 |
| 2023-12-31 | 1.12 |
| 2023-09-30 | 1.05 |
| 2023-06-30 | 1.05 |
| 2023-03-31 | 1.02 |
| 2022-12-31 | 1.05 |
| 2022-09-30 | 0.92 |
| 2022-06-30 | 1.00 |
| 2022-03-31 | 1.19 |
| 2021-12-31 | 1.06 |
| 2021-09-30 | 0.98 |
| 2021-06-30 | 0.89 |
| 2021-03-31 | 0.81 |
| 2020-12-31 | 0.67 |
| 2020-09-30 | 0.64 |
| 2020-06-30 | 0.65 |
| 2020-03-31 | 0.94 |
| 2019-12-31 | 0.76 |
| 2019-09-30 | 0.67 |
| 2019-06-30 | 0.75 |
| 2019-03-31 | 0.76 |
| 2018-12-31 | 0.99 |
| 2018-09-30 | 0.00 |
| 2018-06-30 | 0.00 |
| 2018-03-31 | 0.00 |
